Filing Flows › Opko Health (OPK) › Q3 2026 › vs Q2 2026
Opko Health (OPK) Q3 2026 vs Q2 2026 (quarter over quarter)
Opko Health's revenue fell $98.2M (-60%) from $164M in Q2 2026 to $65.4M in Q3 2026.
Opko Health, Q3 2026: revenue $65.4M (+16% year over year), operating margin -48.0%, net loss $53.5M, operating cash flow −$36.3M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $65.4M | $164M | −$98.2M | -60% |
| Income tax benefit | $7.3M | $5.0M | $2.3M | +47% |
| Net loss | $53.5M | $8.4M | $45.1M | +536% |
| Costs & expenses | $126M | $177M | −$50.7M | -29% |
| Operating costs | $96.8M | $171M | −$73.7M | -43% |
| Interest & other, net | $29.4M | $6.4M | $23.0M | +358% |
| Cost of revenue | $23.4M | $83.6M | −$60.2M | -72% |
| Research & development | $32.2M | $33.2M | −$989K | -3% |
| SG&A | $24.8M | $52.9M | −$28.1M | -53% |
| Other operating costs | $16.5M | $899K | $15.6M | 18× |
| Operating cash sources | $61.0M | $68.1M | −$7.1M | -10% |
| Depreciation & amortization | $22.7M | $22.4M | $318K | +1% |
| Share-based compensation | $2.0M | $2.2M | −$201K | -9% |
| Cash used in operations | $36.3M | $43.5M | −$7.2M | -17% |
| Net loss absorbed | $53.5M | $8.4M | $45.1M | +536% |
| Working capital & other | $7.5M | $59.7M | −$52.2M | -87% |
Questions
How much did Opko Health's revenue grow quarter over quarter in Q3 2026?
Opko Health's revenue fell $98.2M (-60%) from $164M in Q2 2026 to $65.4M in Q3 2026.